Morgan Stanley Downgrades QLT Inc (QLTI) to Underweight
More News related to QLTI
- QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
- QLT announces positive results from the evaluation of Visudyne(R) combination therapy
- Massachusetts Court Dismisses All Claims Filed by MGH Against QLT Inc. (QLTI) Except Those Under Chapter 93A
- QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
- QLT (QLTI) Swings to Q1 Profit
Morgan Stanley downgrades QLT Inc (Nasdaq: QLTI) from Equalweight to Underweight.
QLT Inc. is a global biopharmaceutical company with two commercial products, Visudyne and Eligard, which were derived from its two technology platforms, photodynamic therapy and Atrigel.
Related Categories
DowngradesStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
